Patient & Survivor Care
Feature
Urine Test Could Prevent Unnecessary Prostate Biopsies
Quantitative PCR analysis of 54 candidate genes was performed on urine samples that had been prospectively collected before biopsy.
Conference Coverage
Most women can conceive after breast cancer treatment
In a modern cohort of patients under 40 without metastatic disease, financial status and egg or embryo freezing — but not chemotherapy — affected...
Latest News
Is Vaginal Estrogen Safe in Breast Cancer Survivors?
Study results suggest that estrogen therapy “is safe in individuals with HR-negative tumors and in those concurrently treated with tamoxifen.”
Conference Coverage
Research Highlights From ESMO Breast Cancer
An international panel provided insights on notable breast cancer research.
Feature
Does More Systemic Treatment for Advanced Cancer Improve Survival?
Researchers evaluate whether patients treated in practices with higher rates of systemic therapy for very advanced disease have longer survival....
Feature
Liposomal Irinotecan for Pancreatic Cancer: Is It Worth It?
Oncologists expressed serious doubts about whether the potential benefits of irinotecan liposome are worth the extra cost.
Feature
Urine Tests Could Be ‘Enormous Step’ in Diagnosing Cancer
Cancer biomarkers in urine are not nearly as widely studied as those in the blood, but a new wave of urine tests suggests research is gaining pace...
Conference Coverage
Statin Use May Extend Life for Early Breast Cancer Patients
Data from an emulation trial drew attention with a simple strategy that might improve outcomes for patients with breast cancer.
Conference Coverage
New Immunotherapy Combo Shows Promise for Triple-Negative Breast Cancer
An ongoing trial is evaluating multiple treatment combinations in patients with locally advanced or metastatic TNBC.
Conference Coverage
ART Safe for Breast Cancer Survivors with BRCA1/2 Mutations
Researchers compare maternal and fetal outcomes between those who conceived spontaneously versus those using ART in this high-risk population
Conference Coverage
No Improvement in OS With Atezolizumab in Early Relapsing TNBC
Results “highlight the importance of recognizing TNBC heterogeneity, especially in the first-line setting,” says author of new research.